Prime Medicine PRME 深 滬
等待開盤 08-21 09:30:00 美东时间
3.24
-0.300
-8.47%
華盛通- 最 高3.50
- 今 開3.43
- 成交量 379.33万股
- 最 低 3.20
- 昨 收 3.54
- 總市值 5.88亿
- 52周最高 6.94
- 市盈率 靜 --
- 換手率 2.09%
- 52周最低 2.67
- 委 比 -21.35%
- 總股本 1.81亿
- 歷史最高 21.73
- 量 比 1.46
- 振 幅 8.47%
- 歷史最低 1.11
- 每 手 1
- 風險率 0.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅1610.53%！Ascendiant Capital上调Alzamend Neuro目标价至26美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Alzamend Neuro"买入"评级，目标价从25美元升至26美元；Tigress Financial：维持Legence"买入"评级，目标价从125美元升至130美元
08-20 08:39
BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9
BMO Capital analyst David Lebowitz initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $9.
08-19 18:21
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
Prime Medicine Q2 EPS $(0.24) Beats $(0.26) Estimate, Sales $1.154M Miss $1.295M Estimate
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 41.46 percent increase over losses of $(0.41) per share from the same period last year. The company reported quarterly sales of $1.154 million w...
08-06 20:01
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine reported Q2 2026 financial results with $108.8M in cash and provided updates on its pipeline. The company secured IND/CTA clearances for PM577a in Wilson disease, resolving arbitration for PM647 in Alpha-1 Antitrypsin Deficiency, and received FDA RMAT designation for PM359. Clinical data for both PM577a and PM647 are expected in 2027, with PM359 targeting a BLA submission in H1 2027. The company remains focused on advancing its Pri...
08-06 12:00
Cathie Wood's Ark Invest boosts stakes in Tesla, SpaceX, Meta, trimming Figma, Shopify
Cathie Wood’s ARK Invest’s largest purchase during July 20-24 was Tesla (TSLA), with the firm acquiring an additional $52.7M stake after a steep sell-off post weaker-than-expected Q2 earnings report. ...
07-27 19:05
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
Prime Medicine's PM577a, an in vivo Prime Editor targeting the H1069Q mutation in the ATP7B gene for Wilson disease, has received FDA clearance for its IND application, enabling U.S. clinical studies. Combined with prior New Zealand CTA approval, this establishes a global Phase 1/2 trial program. PM577a aims to offer a one-time curative therapy addressing the genetic root of WD, with initial clinical data expected in 2027.
07-23 20:05
美股牛股 | AI基建供应商PENG涨逾25%！季报营收大超预期；金山云升逾11%，受益于小米算力投入激增
AI基建供应商PENG涨逾25%！季报营收大超预期；WULF涨近13%，此前与Anthropic签署20年超级租赁协议；金山云升逾11%，受益于小米算力投入激增>>
07-09 18:44
Prime Medicine resolves arbitration, clarifying PM647 development rights
The latest announcement is out from Prime Medicine, Inc. ( ($PRME) ). On July 6...
07-08 20:29
Tribunal Declares Prime Medicine's PM657 Is Within It's "Field" As Defined By Agreement With Beam Therapeutics; Company Owes No Monetary Damages To Beam
Tribunal Declares Prime Medicine's PM657 Is Within It's "Field" As Defined By Agreement With Beam Therapeutics; Company Owes No Monetary Damages To Beam
07-08 20:03
